報價延遲最少15分鐘:2026/04/15 09:30 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3726 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.25/-0.26
|
|
企業價值
14.28M
|
| 資產負債 |
|
每股賬面淨值
-0.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
21.80K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line. |
